In yesterday’s Wall Street session, BridgeBio Pharma Inc (NASDAQ:BBIO) shares traded at $27.85, up 13.12% from the previous session.
BBIO stock price is now 8.63% away from the 50-day moving average and -7.41% away from the 200-day moving average. The market capitalization of the company currently stands at $5.24B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
On January 31, 2024, BMO Capital Markets recently initiated its ‘Market Perform’ rating on the stock quoting a target price of $37, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, Kumar Neil, Chief Executive Officer sold 27,389 shares of the company’s stock on Aug 19 ’24. The stock was sold for $676,256 at an average price of $24.69. Upon completion of the transaction, the Chief Executive Officer now directly owns 4,897,443 shares in the company, valued at $136.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 19 ’24, Secretary, Treasurer & CFO STEPHENSON BRIAN C sold 4,155 shares of the business’s stock. A total of $102,590 was realized by selling the stock at an average price of $24.69. This leaves the insider owning 85,192 shares of the company worth $2.37 million. A total of 25.10% of the company’s stock is owned by insiders.
During the past 12 months, BridgeBio Pharma Inc has had a low of $21.62 and a high of $44.32. The fifty day moving average price for BBIO is $25.6542 and a two-hundred day moving average price translates $30.080025 for the stock.
The latest earnings results from BridgeBio Pharma Inc (NASDAQ: BBIO) was released for 2024-06-30. The company reported revenue of $2.17 million for the quarter, compared to $1.64 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.11 percent.
